What one share of Aytu BioPharma holds
Aytu BioPharma, Inc. (“Aytu,” the “Company,” “we,” “us,” or “our”) is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients.
Aytu BioPharma’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $4.67 |
|---|---|
| Profit | −$1.16 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | $0.26 |
| Cash and investments | $2.45 |
| Debt | $1.02 |
| Book value | $3.29 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $187.83 | −$696.18 | $1.54 | −$356.44 | — | — |
| 2020 | $122.29 | −$60.28 | $0.00 | −$125.57 | — | — |
| 2021 | $78.38 | −$69.61 | $2.80 | −$33.80 | — | $100.08 |
| 2022 | $65.77 | −$74.01 | $0.00 | −$19.61 | — | $22.97 |
| 2023 | $32.16 | −$5.11 | — | — | — | $7.13 |
| 2024 | $11.77 | −$2.86 | $0.06 | −$0.31 | — | $4.64 |
| 2025 | $10.57 | −$2.16 | $0.04 | −$0.34 | — | $2.11 |
| 2026 | $4.67 | −$1.16 | $0.00 | $0.26 | — | $3.29 |
Common questions about Aytu BioPharma
How much does one share of Aytu BioPharma earn?
Over its latest fiscal year, Aytu BioPharma lost $1.16 for each share on $4.67 of sales.
Does Aytu BioPharma pay a dividend?
Aytu BioPharma didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is Aytu BioPharma’s book value per share?
Aytu BioPharma’s book value is $3.29 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Aytu BioPharma have?
Each share of Aytu BioPharma has $2.45 of cash and investments and $1.02 of debt, as of June 30, 2026.
What is Aytu BioPharma’s free cash flow per share?
$0.26 per share over its latest fiscal year. Free cash flow is the cash left over after spending on buildings and equipment.
Has Aytu BioPharma bought back shares?
Aytu BioPharma’s share count rose about 31509% from 2019 to 2026. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.